NCT04086147

CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase

Chinese Acute Tissue-based Imaging Selection for Lysis in Stroke: a Prospective, Multicentre, Randomized, Open-label, Rater-blinded, Randomized Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 86 (actual)
• Sponsor: Huashan Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To select the best dosage of tenecteplase for acute ischemic stroke patients (onset time 4.5-24h) of large vessel occlusion using early combined CT/MR imaging outcomes

Conditions

• Stroke

Interventions

Type	Name	Description
DRUG	Low dose tenecteplase	Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
DRUG	High dose tenecteplase	Intravenous (IV) tenecteplase 0.32 mg/kg (single bolus; maximum dose 32 mg)

Timeline

• Start date: 2019-12-09
• Primary completion: 2021-12-31
• Completion: 2021-12-31
• First posted: 2019-09-11
• Last updated: 2022-03-31

Locations

1 site across 1 country: China